Hillhouse Capital Management LTD. acquired a new position in Hookipa Pharma Inc (NASDAQ:HOOK) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 657,540 shares of the company’s stock, valued at approximately $4,425,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of HOOK. Tower Research Capital LLC TRC bought a new position in shares of Hookipa Pharma in the 2nd quarter worth about $40,000. Northern Trust Corp bought a new position in shares of Hookipa Pharma in the 2nd quarter worth about $72,000. Morgan Stanley bought a new position in shares of Hookipa Pharma in the 2nd quarter worth about $99,000. Vanguard Group Inc. bought a new position in shares of Hookipa Pharma in the 2nd quarter worth about $538,000. Finally, BlackRock Inc. bought a new position in shares of Hookipa Pharma in the 2nd quarter worth about $737,000. Institutional investors and hedge funds own 30.36% of the company’s stock.
Shares of NASDAQ HOOK opened at $7.92 on Friday. The company’s 50-day moving average is $7.57. The company has a current ratio of 8.69, a quick ratio of 8.69 and a debt-to-equity ratio of 0.08. Hookipa Pharma Inc has a 52-week low of $6.06 and a 52-week high of $14.76.
Several research analysts recently issued reports on HOOK shares. Royal Bank of Canada reiterated a “buy” rating and issued a $23.00 price target on shares of Hookipa Pharma in a research note on Wednesday, August 14th. Zacks Investment Research downgraded shares of Hookipa Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $17.55.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Further Reading: How accurate is the Rule of 72?
Want to see what other hedge funds are holding HOOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hookipa Pharma Inc (NASDAQ:HOOK).
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.